TAK 831

Drug Profile

TAK 831

Alternative Names: TAK-831

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antipsychotics
  • Mechanism of Action D amino acid oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Friedreich's ataxia
  • Phase I Ataxia; Schizophrenia

Most Recent Events

  • 02 Dec 2017 Takeda plans a phase II trial for Schizophrenia in December 2017 (NCT03359785)
  • 08 Nov 2017 Phase-II clinical trials in Friedreich's ataxia in USA (PO) (NCT03214588)
  • 25 Jul 2017 Takeda plans a phase I trial in Healthy volunteers in USA (NCT03224325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top